Nick A Francis1, Matthew J Ridd2, Emma Thomas-Jones3, Christopher C Butler4, Kerenza Hood3, Victoria Shepherd3, Charis A Marwick5, Chao Huang3, Mirella Longo6, Mandy Wootton7, Frank Sullivan8. 1. Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, Wales francisna@cf.ac.uk. 2. School of Social and Community Medicine, University of Bristol, Bristol, England. 3. South East Wales Trials Unit, Centre for Trials Research, Cardiff University, Cardiff, Wales. 4. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, England. 5. Population Health Sciences, University of Dundee, Dundee, Scotland. 6. Swansea Centre for Health Economics, Swansea University, Swansea, Wales. 7. Specialist Antimicrobial Chemotherapy Unit, Public Health Wales, University Hospital Wales, Cardiff, Wales. 8. Department of Family & Community Medicine and Dalla Lana School of Public Health, North York General Hospital, University of Toronto, Toronto, Canada.
Abstract
PURPOSE: Eczema may flare because of bacterial infection, but evidence supporting antibiotic treatment is of low quality. We aimed to determine the effect of oral and topical antibiotics in addition to topical emollient and corticosteroids in children with clinically infected eczema. METHODS: We employed a 3-arm, blinded, randomized controlled trial in UK ambulatory care. Children with clinical, non-severely infected eczema were randomized to receive oral and topical placebos (control), oral antibiotic (flucloxacillin) and topical placebo, or topical antibiotic (fusidic acid) and oral placebo, for 1 week. We compared Patient Oriented Eczema Measure (POEM) scores at 2 weeks using analysis of covariance (ANCOVA). RESULTS: We randomized 113 children (40 to control, 36 to oral antibiotic, and 37 to topical antibiotic). Mean (SD) baseline Patient Oriented Eczema Measure scores were 13.4 (5.1) for the control group, 14.6 (5.3) for the oral antibiotic group, and 16.9 (5.5) for the topical antibiotic group. At baseline, 104 children (93%) had 1 or more of the following findings: weeping, crusting, pustules, or painful skin. Mean (SD) POEM scores at 2 weeks were 6.2 (6.0) for control, 8.3 (7.3) for the oral antibiotic group, and 9.3 (6.2) for the topical antibiotic group. Controlling for baseline POEM score, neither oral nor topical antibiotics produced a significant difference in mean (95% CI) POEM scores (1.5 [-1.4 to 4.4] and 1.5 [-1.6 to 4.5] respectively). There were no significant differences in adverse effects and no serious adverse events. CONCLUSIONS: We found rapid resolution in response to topical steroid and emollient treatment and ruled out a clinically meaningful benefit from the addition of either oral or topical antibiotics. Children seen in ambulatory care with mild clinically infected eczema do not need treatment with antibiotics.
RCT Entities:
PURPOSE:Eczema may flare because of bacterial infection, but evidence supporting antibiotic treatment is of low quality. We aimed to determine the effect of oral and topical antibiotics in addition to topical emollient and corticosteroids in children with clinically infected eczema. METHODS: We employed a 3-arm, blinded, randomized controlled trial in UK ambulatory care. Children with clinical, non-severely infected eczema were randomized to receive oral and topical placebos (control), oral antibiotic (flucloxacillin) and topical placebo, or topical antibiotic (fusidic acid) and oral placebo, for 1 week. We compared Patient Oriented Eczema Measure (POEM) scores at 2 weeks using analysis of covariance (ANCOVA). RESULTS: We randomized 113 children (40 to control, 36 to oral antibiotic, and 37 to topical antibiotic). Mean (SD) baseline Patient Oriented Eczema Measure scores were 13.4 (5.1) for the control group, 14.6 (5.3) for the oral antibiotic group, and 16.9 (5.5) for the topical antibiotic group. At baseline, 104 children (93%) had 1 or more of the following findings: weeping, crusting, pustules, or painful skin. Mean (SD) POEM scores at 2 weeks were 6.2 (6.0) for control, 8.3 (7.3) for the oral antibiotic group, and 9.3 (6.2) for the topical antibiotic group. Controlling for baseline POEM score, neither oral nor topical antibiotics produced a significant difference in mean (95% CI) POEM scores (1.5 [-1.4 to 4.4] and 1.5 [-1.6 to 4.5] respectively). There were no significant differences in adverse effects and no serious adverse events. CONCLUSIONS: We found rapid resolution in response to topical steroid and emollient treatment and ruled out a clinically meaningful benefit from the addition of either oral or topical antibiotics. Children seen in ambulatory care with mild clinically infected eczema do not need treatment with antibiotics.
Authors: Kam Lun Hon; Shuxin Susan Wang; Kenneth K C Lee; Vivian W Y Lee; Ting Fan Leung; Margaret Ip Journal: J Drugs Dermatol Date: 2012-07 Impact factor: 2.114
Authors: J E E Totté; W T van der Feltz; M Hennekam; A van Belkum; E J van Zuuren; S G M A Pasmans Journal: Br J Dermatol Date: 2016-07-05 Impact factor: 9.302
Authors: H C Williams; P G Burney; R J Hay; C B Archer; M J Shipley; J J Hunter; E A Bingham; A Y Finlay; A C Pembroke; R A Graham-Brown Journal: Br J Dermatol Date: 1994-09 Impact factor: 9.302
Authors: Matthew J Ridd; Kirsty Garfield; Daisy M Gaunt; Sandra Hollinghurst; Niamh M Redmond; Kingsley Powell; Victoria Wilson; Richard H Guy; Nicola Ball; Lindsay Shaw; Sarah Purdy; Chris Metcalfe Journal: BMJ Open Date: 2016-11-16 Impact factor: 2.692
Authors: Anneliese Willems; Amanda Tapley; Alison Fielding; Er Tsing Vivian Tng; Elizabeth G Holliday; Mieke L van Driel; Jean I Ball; Andrew R Davey; Irena Patsan; Kristen FitzGerald; Neil A Spike; Parker J Magin Journal: Dermatol Pract Concept Date: 2021-09-01
Authors: L Howells; S Gran; J R Chalmers; B Stuart; M Santer; L Bradshaw; D M Gaunt; M J Ridd; L A A Gerbens; P I Spuls; C Huang; N A Francis; K S Thomas Journal: Skin Health Dis Date: 2021-05-19
Authors: Lawrence F Eichenfield; Stephen Stripling; Selwyn Fung; Amy Cha; Andryann O'Brien; Lawrence A Schachner Journal: Paediatr Drugs Date: 2022-06-13 Impact factor: 3.930
Authors: Victoria Shepherd; Emma Thomas-Jones; Matthew J Ridd; Kerenza Hood; Katy Addison; Nick A Francis Journal: Trials Date: 2017-11-10 Impact factor: 2.279
Authors: Kay Wang; Tricia Carver; Sharon Tonner; Malcolm G Semple; Alastair D Hay; Michael Moore; Paul Little; Christopher Butler; Andrew Farmer; Rafael Perera; Ly-Mee Yu; Susan Mallett; Jane Wolstenholme; Anthony Harnden Journal: BMJ Open Date: 2018-05-16 Impact factor: 2.692
Authors: C P Harkins; M A McAleer; D Bennett; M McHugh; O M Fleury; K A Pettigrew; K Oravcová; J Parkhill; C M Proby; R S Dawe; J A Geoghegan; A D Irvine; M T G Holden Journal: Br J Dermatol Date: 2018-07-24 Impact factor: 9.302